## Uptravi (selexipag) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME		_ MEMBER'S FIRST	NAME:	
that is important for the re		lab data, to support the	y. Attach any additional documentation ne authorization request). Information	
			☐ URGENT	
MEMBER INFORMATION	DN			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE	ID NUMBER:			
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG):	ALLERGIES:	
DISCLOSURE AUTHOR FOLLOWING LINK: PRI	METHERAPEUTICS.COM D REPRESENTATIVE (IF	IIS REQUEST WHICI M/NOPP F APPLICABLE):	H CAN BE FOUND AT THE	
AUTHORIZED REPRESI	ENTATIVE'S PHONE NUI	MBER:		
PRESCRIBER INFORM	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:		·		
CITY:		STATE:	STATE: ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTACT PERSON:		
		,		
	ICAL DISPENSING INFO	RMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REF	QUANTITY:	
☐ NEW THERAPY	RENEWAL IF		HERAPY INITIATED:	
DURATION OF THERA	PY (SPECIFIC DATES):			
Continued on next page				

© 2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.10.24 CAT009



## Uptravi (selexipag) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:
	OTHER MEDICATIONS FOR THIS	CONDITION?
YES (if yes, complete below)  MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
☐ Pulmonary arterial hypertension☐ Other diagnosis:		
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIZ	<b>ATION:</b> PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION
Is Uptravi being prescribed by a positive No  Does the patient have a diagnosis  Select if the patient's pulmonary and Idiopathic/Primary PAH  Drug- and toxin-induced  Connective tissue disease (esyndrome, polymyositis, polyally HIV infection  Portal hypertension  Congenital heart disease  Schistosomiasis	in combination with a clinical trial oulmonologist, cardiologist, nephrons of pulmonary arterial hypertensic arterial hypertension (PAH) was case.g., Lupus/SLE, RA scleroderma, sarteritis nodosa, mixed connective	ologist, or rheumatologist? □ Yes on (WHO Group 1)? □ Yes □ No used by the following: systemic sclerosis, CREST
□ Chronic hemolytic anemia	) Functional Class II through IV syr	mntoms? □ Vos □ No
Select if the patient's cardiac cath Does patient have, (at rest), meas pressure(mPAP of 20mmHg or graph provide documentation.	heterization report meets any of the sured by cardiac catheterization a r reater via right heart cath to confirn	· e following:* mean pulmonary artery n PAH? □ Yes □ No <i>*Pleas</i> e
	sured by cardiac catheterization a position in the sure of the sur	
	sured by cardiac catheterization a p wood units or greater via right hea on	

<sup>© 2024</sup> Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 12.10.24 CAT009



## **Uptravi** (selexipag) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
Has the patient tried and had an inadeq Adcirca) OR Adempas (riociguat)?* □ Yo *Please provide documentation.	uate response or intolerance to PDE5 inhibitor (i.e. Revatio, es □ No			
Does the patient have a contraindication Adcirca) and Adempas (riociguat)?* □ Y** *Please submit documentation of the co				
	uate response or intolerance to an endothelin receptor Opsumit (macitentan), or Tracleer (bosentan)]?* □ Yes □ No			
	n to treatment w ith an endothelin receptor antagonist [e.g., entan), or Tracleer (bosentan)]?* □ Yes □ No ntraindication.			
Will Uptravi be taken in combination will iloprost, treprostinil)? □ Yes □ No	ith a prostanoid/prostacyclin analogue (e.g., epoprostenol,			
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
required information is received.	covered on all plans. This request may be denied unless all			
understand that the Health Plan, insurer, N	rovided is true and accurate to the best of my knowledge. I Medical Group or its designees may perform a routine audit and to verify the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. \	/erification: Date:			
	ents accompanying this transmission contain confidential health			
	are not the intended recipient, you are hereby notified that any taken in reliance on the contents of these documents is strictly			

**FAX THIS FORM TO:** 800-424-7640

prohibited. If you have received this information in error, please notify the sender immediately (via return

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811

Phone: 877-228-7909



FAX) and arrange for the return or destruction of these documents.